Citation: | ZHU Bao, JIN Shuanglong, GUO Yi, LI Yuezhen, ZHANG Yihua, LAI Yisheng. Design, synthesis and biological evaluation of pyridine-based IRAK4 inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(6): 670-674. DOI: 10.11665/j.issn.1000-5048.20170606 |
[1] |
Li S,Strelow A,Fontana EJ,et al.H.IRAK-4:a novel member of the IRAK family with the properties of an IRAK-kinase [J].Proc Natl Acad Sci,2002,99(8):5567-5572.
|
[2] |
Takeda K,Akira S.TLR signaling pathways[J].Semin Immunol,2004,16(1):3-9.
|
[3] |
Suzuki N,Suzuki S,Duncan GS,et al.Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK4[J].Nature, 2002,416(6882):750-756.
|
[4] |
Ngo VN,Young RM,Schmitz R,et al.Oncogenically active MYD88 mutations in human lymphoma[J].Nature,2011,470(7332):115-119.
|
[5] |
Yang,G,Zhou Y,Liu X,et al.A mutation in MYD88(L265P)supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia[J].Blood,2013,122(7):1222-1232.
|
[6] |
Chaudhary D,Robinson S,Romero DL.Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4(IRAK4)as a therapeutic target for inflammation and oncology disorders[J].J Med Chem,2015,58(1):96-110.
|
[7] |
Anastassiadis T,Deacon SW,Devarajan K,et al.Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity[J].Nat Biotechnol,2011,29(11):1039-1045.
|